Le Lézard
Subject: ATY

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

NEW YORK, Dec. 3, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in connection with the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas Pharma") (OTC:ALPMY).  Under the terms of the acquisition agreement, BOLD shareholders will receive $60.00 per share in cash. 

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

If you are a shareholder and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771

WeissLaw is investigating whether Audentes' Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, the deal gives Astellas access to AT132, the Company's lead gene replacement therapy program, which has shown a promising safety and efficacy profile in patients with a rare neuromuscular disorder.  Finally, the merger agreement has a "No Solicitation" provision barring Audentes from discussing any acquisition proposals from another party. 

Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com


News published on 3 december 2019 at 19:13 and distributed by: